Get started
Author

Merve Gökçen Polat

Observed names: Merve Gokcan Polat, Merve Gokcen Polat, POLAT, MERVE GÖKÇEN
ORCID: 0000-0001-9797-3922
Observed ORCID: 0000-0001-9797-3922
OpenAlex ID: A5073023274
Serum calprotectin (S100A8/A9) levels as a new potential biomarker of treatment response in Hodgkin lymphoma
2021 · Şeyma Şumnu, Özgür Mehtap, et al. · International Journal of Laboratory Hematology · 17
Effects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma
2022 · Ayfer Geduk¹, Berrin Oztas, et al. · Indian Journal of Hematology and Blood Transfusion · 5
PDF
Role of serum calprotectin in identifying familial Mediterranean fever attacks
2024 · Merve Gokcen Polat, Ahmet Omma, et al. · Irish Journal of Medical Science (1971 -) · 3
Idarubicin Versus Daunorubicin Versus Mitoxantrone for Induction Chemotherapy in Acute Myeloid Leukemia: Patient Registration Study of Turkish Society of Hematology-Acute Myeloid Leukemia Working Group
2023 · Ibrahim Ethem Pinar, Serhat Celik, et al. · Blood · 3
Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data
2023 · Müzeyyen Aslaner Ak, Ayfer Gedük, et al. · Turkish Journal of Hematology · 3
PDF
The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study
2021 · Muzeyyen Aslaner Ak, Birsen Sahip, et al. · Indian Journal of Hematology and Blood Transfusion · 3
Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project
2025 · Ibrahim Ethem Pinar, Serhat Celik, et al. · BMC Cancer · 2
PDF
Acute Myeloid Leukemia in Elderly, Unfit Patients: Analysis of Turkish AML Prospective Registry Database, on Behalf of Acute Leukemia Working Group of Turkish Society of Hematology
2023 · Selin Merih Urlu, Guldane Cengiz Seval, et al. · Blood · 2
The Evaluation of Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients
2021 · Sinan Mersin, Ayfer Gedük, et al. · Turkish Journal of Hematology · 2
PDF
Clinical Characteristics, Treatment Approaches, and Survival Predictors in Adult Acute Myeloid Leukemia: Interim Results from the Turkish Society of Hematology AML Registry
2025 · Volkan Karakus, Ibrahim Ethem Pinar, et al. · Journal of Clinical Medicine · 1
PDF
Do Alarmins Have a Role in Multiple Myeloma?
2024 · Ayfer Gedük, Merve Gökçen Polat, et al. · Turkish Journal of Hematology · 1
PDF
AML-556: Personalized Therapy and Real-World Outcomes in Adult Acute Myeloid Leukemia: Lessons From a Nationwide Prospective Cohort in Turkey
2025 · Volkan Karakus, Ibrahim Ethem Pinar, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-556 Personalized Therapy and Real-World Outcomes in Adult Acute Myeloid Leukemia: Lessons From a Nationwide Prospective Cohort in Turkey
2025 · Volkan Karakus, İbrahim Ethem Pinar, et al. · Clinical Lymphoma Myeloma & Leukemia
Prospective Real-World Outcomes of Acute Myeloid Leukemia
2023 · Volkan Karakus, Utku Iltar, et al. · Blood
PDF
Multi̇pl Mi̇yelomda Alarmi̇nleri̇n Rolü Var Mi?
2023 · EROL, HAŞİM ATAKAN, ÖZTAŞ, BERRİN, et al. · Kocaeli Üniversitesi - AVESİS
The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients With Low-risk or Intermediate-1-risk Myelodysplastic Syndrome: Retrospective Multi-center Real-life Study
2023 · Müzeyyen Aslaner Ak, Birsen Sahip, et al. · Hematology Transfusion and Cell Therapy
The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data
2023 · GEDÜK, AYFER, GÜVENÇ, BİROL, et al. · Kocaeli Üniversitesi - AVESİS
POSTER: MDS-225 The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data
2023 · Müzeyyen Aslaner Ak, Ayfer Gedük, et al. · Clinical Lymphoma Myeloma & Leukemia
MDS-225 The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data
2023 · Müzeyyen Aslaner Ak, Ayfer Gedük, et al. · Clinical Lymphoma Myeloma & Leukemia
Correction to: Efects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma
2023 · Ayfer Geduk, Berrin Oztas, et al. · Indian Journal of Hematology and Blood Transfusion
PDF
Retrospective Analysis of Turkish AML Registry Database, on Behalf of AML Working Group of Turkish Society of Hematology
2022 · Volkan Karakuş, Omur Gokmen Sevindik, et al. · Blood
İnhi̇bi̇törlü Bi̇r Hemofi̇li̇ Hastasinda Port Kateteri̇ Takilmasisonrasi Geli̇şen Hematoraks Ve Yöneti̇mi̇
2022 · YENİHAYAT, EMEL MERVE, MEHTAP, ÖZGÜR, et al. · Kocaeli Üniversitesi - AVESİS
Igg Mgus Eşli̇k Eden Von Wi̇llebrand Hastaliği
2022 · ÜNAL, SERKAN, MERSİN, SİNAN, et al. · Kocaeli Üniversitesi - AVESİS
Gebeli̇kte Faktör X Eksi̇kli̇ği̇ Profi̇lakti̇k Tedavi̇ Ve Yöneti̇mi̇
2022 · HACİHANİFİOĞLU, ABDULLAH, AYGÜN, KEMAL, et al. · Kocaeli Üniversitesi - AVESİS
Relaps/refrakter Tüylü Hücreli̇ Lösemi̇ Olgusunda Vemurafeni̇b Tedavi̇si̇: Olgu Sunumu
2021 · HACİHANİFİOĞLU, ABDULLAH, ALBAYRAK, HAYRUNNİSA, et al. · Kocaeli Üniversitesi - AVESİS
Works count: 39
Citation count: 42
H-index: 3
I10-index: 1
Year
Topic
Type